The up-take of AIMSPRO on the Named Patient programme has shown that AIMSPRO has the potential to be marketed on a broad basis. In order to support an application for marketing approval, Daval has undertaken Phase II studies but anticipates the need for larger multi-centre Phase III clinical studies. Daval does not have a marketing group and these are its only products in development. Among other options, Daval has decided to look for a suitable partner to undertake the further development and commercialisation of the product. Daval believes that AIMSPRO will achieve marketing authorisation sooner with the resources and support of a larger pharmaceutical company.
Daval is prepared to grant an exclusive worldwide license to all of its intellectual property rights in AIMSPRO for human use. The structure of any licence will be based on the development plans of the potential partner and would include a signature fee, with milestones to be paid against achievement of particular development objectives and royalties. Daval will look for commitments on the part of its licensee to develop the product in key indications. On an expression of interest we would propose a meeting between Daval personnel and your licensing / business development executives under confidentiality, when we would be able to disclose further information regarding AIMSPRO.
Daval’s licensing programme is being coordinated by Edward Jensen and James D. Shotton at Daval. Interested parties can contact Edward (Email : edward.jensen@davalinternational.com; Telephone : +44 7775 793513 or +1 484 716 9305) or James (james.shotton@davalinternational.com; Telephone : +44 7739 648401 or +1 303 588 5881) in the first instance to register their interest and to obtain further information.